Molecular characterization and therapeutic targeting of Protein Kinase D2 in t(4;14) multiple myeloma

Funding Cycle:

2023-2024

Name:

Raphael Szalat

Type of Award:

Translational Research Award

Home Institution:

Boston Medical Center

Description

This project aims to molecularly characterize and target Protein Kinase D2 (PRKD2) in t(4;14) multiple myeloma (MM), a high-risk subgroup of MM with poor outcomes. Specific aims include validating the functional role of PRKD2 in MM cells through transcriptomic and epigenomic studies, and evaluating the therapeutic potential of targeting PRKD2 and its downstream pathways using in vitro and in vivo models. The project aims to identify novel therapeutic strategies for t(4;14) MM, potentially leading to clinical trials for new targeted therapies.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

See All of the Member Benefits

Become a Member Today